Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Institut national de la recherche scientifique

$30,000.00

Interactions of natural and synthetic compounds with steroidogenic enzymes and sex hormone receptor signalling

EF 2011-12

Résumé
There is increasing societal concern regarding chemicals that may disrupt endocrine processes, potentially resulting in reproductive problems, certain cancers and other toxicities related to (sexual) differentiation, growth and development. Various compounds have been identified as inhibitors of steroidogenesis, including pesticides, drugs and natural compounds. Most of these are in vitro studies, few in vivo studies exist. Aromatase (CYP19) and steroid 5alpha-reductase (SRD5A) are of particular interest as they are the key steroidogenic enzymes producing the most potent estrogens and androgens, 17ß-estradiol and DHT, respectively, and are involved in various endocrine pathologies. We hypothesize that natural or synthetic compounds with structures resembling the endogenous androgens (androstenedione, testosterone) act as inhibitors of CYP19 and SRD5A activity (which utilize androgens as natural substrates) and as antagonists of the androgen receptor (AR). The objectives of my research programme are to 1) identify the structural requirements of natural or synthetic chemicals enabling them to interfere with the catalytic activity or gene expression of the CYP19 and SRD5A, as well as with AR signalling; 2) elucidate mechanisms (signalling pathways involved) of enzyme inhibition/induction or AR ant(agonism) in vitro in cell-based assays; 3) evaluate the biological activity of these compounds in vivo in bioluminescent mouse models or mice bearing bioluminescent human cancer cells. This research programme aims to better understand the mechanisms (signalling pathways) involved in CYP19, SRD5A and AR regulation. It will identify novel structures that may lead to the development of novel CYP19 and SRD5A inhibitors or AR antagonist which could be used to treat certain cancers and other diseases. It will evaluate the effectiveness in vivo of compounds shown to be active in vitro. This will provide important information allowing us to determine under which conditions it is valid to extrapolate in vitro effects to an in vivo situation.
Programme
Discovery Grants Program - Individual
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
313313-2011
Name nom
Sanderson, Thomas
Department département
INRS-Institut Armand-Frappier
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
30000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6403
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Toxicology
Research subject fr
Toxicologie
Partie
1
Nb partie
1
Application title
Interactions of natural and synthetic compounds with steroidogenic enzymes and sex hormone receptor signalling
Keyword
NSERC
Application summary
There is increasing societal concern regarding chemicals that may disrupt endocrine processes, potentially resulting in reproductive problems, certain cancers and other toxicities related to (sexual) differentiation, growth and development. Various compounds have been identified as inhibitors of steroidogenesis, including pesticides, drugs and natural compounds. Most of these are in vitro studies, few in vivo studies exist. Aromatase (CYP19) and steroid 5alpha-reductase (SRD5A) are of particular interest as they are the key steroidogenic enzymes producing the most potent estrogens and androgens, 17ß-estradiol and DHT, respectively, and are involved in various endocrine pathologies. We hypothesize that natural or synthetic compounds with structures resembling the endogenous androgens (androstenedione, testosterone) act as inhibitors of CYP19 and SRD5A activity (which utilize androgens as natural substrates) and as antagonists of the androgen receptor (AR). The objectives of my research programme are to 1) identify the structural requirements of natural or synthetic chemicals enabling them to interfere with the catalytic activity or gene expression of the CYP19 and SRD5A, as well as with AR signalling; 2) elucidate mechanisms (signalling pathways involved) of enzyme inhibition/induction or AR ant(agonism) in vitro in cell-based assays; 3) evaluate the biological activity of these compounds in vivo in bioluminescent mouse models or mice bearing bioluminescent human cancer cells. This research programme aims to better understand the mechanisms (signalling pathways) involved in CYP19, SRD5A and AR regulation. It will identify novel structures that may lead to the development of novel CYP19 and SRD5A inhibitors or AR antagonist which could be used to treat certain cancers and other diseases. It will evaluate the effectiveness in vivo of compounds shown to be active in vitro. This will provide important information allowing us to determine under which conditions it is valid to extrapolate in vitro effects to an in vivo situation.